JCR Pharmaceuticals Co., Ltd. Raises Full-Year Earnings Forecast

JCR Pharmaceuticals Co., Ltd. Raises Full-Year Earnings Forecast

JCR Pharmaceuticals Co., Ltd. (TSE:4552) has revised upward its consolidated earnings guidance for the fiscal year ending March 2026, citing stronger-than-expected product sales and foreign exchange gains.

The pharmaceutical company lifted revenue guidance by JPY 800M to JPY 40.3bn, reflecting solid momentum in product sales. Operating profit was increased by JPY 100M to JPY 500M, as gross margins and selling, general and administrative expenses tracked near initial expectations. Most significantly, ordinary income (keijo rieki)—a Japan-specific metric encompassing operating profit plus non-operating items—surged 175% to JPY 1.10bn, driven primarily by anticipated foreign exchange gains. Net profit attributable to parent shareholders was raised JPY 500M to JPY 2.10bn, representing a 31.3% increase from the prior forecast. Earnings per share is now projected at JPY 17.87, up 36.2% from the previous JPY 13.12 guidance.

The revision signals improving operational execution and favorable currency tailwinds for the specialty pharmaceutical manufacturer. The substantial lift in ordinary income underscores the material impact of forex movements on bottom-line results. International investors should note that ordinary income differs materially from operating profit due to the inclusion of financial income and expenses, a distinction unique to Japanese accounting conventions. The upward revision to net profit and EPS suggests management confidence in sustained product demand through the fiscal year-end.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.